Current treatment guidelines for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) recommend multimodal treatment, including chemoradiation therapy (CRT) or surgery followed by radiation, with or without chemotherapy. The immune checkpoint inhibitor pembrolizumab has previously demonstrated antitumor activity in recurrent and/or metastatic HNSCC in large Phase III trials. For patients with locally advanced disease, Phase Ib data on the use of pembrolizumab in combination with chemoradiation have shown the approach to be safe and feasible. We describe here the design and rationale for KEYNOTE-412, a randomized, double-blind, Phase III trial investigating pembrolizumab or placebo administered concurrently with CRT and as maintenance treatment in patients with locally advanced HNSCC. Clinical Trial Registration: NCT03040999 (ClinicalTrials.gov).

Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412 / J. Machiels, Y. Tao, B. Burtness, M. Tahara, L. Licitra, D. Rischin, J. Waldron, C. Simon, V. Gregoire, K. Harrington, G.V. Alves, I.P. Figueiredo Lima, Y. Pointreau, B.G. M Hughes, S. Aksoy, M. Hetnal, J.Y. Ge, H. Brown, J. Cheng, B. Bidadi, L.L. Siu. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - (2020). [Epub ahead of print]

Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412

L. Licitra;
2020

Abstract

Current treatment guidelines for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) recommend multimodal treatment, including chemoradiation therapy (CRT) or surgery followed by radiation, with or without chemotherapy. The immune checkpoint inhibitor pembrolizumab has previously demonstrated antitumor activity in recurrent and/or metastatic HNSCC in large Phase III trials. For patients with locally advanced disease, Phase Ib data on the use of pembrolizumab in combination with chemoradiation have shown the approach to be safe and feasible. We describe here the design and rationale for KEYNOTE-412, a randomized, double-blind, Phase III trial investigating pembrolizumab or placebo administered concurrently with CRT and as maintenance treatment in patients with locally advanced HNSCC. Clinical Trial Registration: NCT03040999 (ClinicalTrials.gov).
PD-1; PD-L1; chemoradiation; head and neck cancer; immune checkpoint blockade; pembrolizumab
Settore MED/06 - Oncologia Medica
2020
3-giu-2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
PMID 32490686.pdf

accesso riservato

Descrizione: Articolo principale
Tipologia: Publisher's version/PDF
Dimensione 294.75 kB
Formato Adobe PDF
294.75 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/738118
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 46
  • ???jsp.display-item.citation.isi??? 40
social impact